News

Oct 4th 2018 Collaborator, Dr. Kazuya Sakai will present data of anti-von Willerbrand Factor A1 domain Xenoligo at the American Society of Hematology

TITLE: Inhibitory Effect of a Novel DNA Aptamer with Artificial Nucleic Bases for Von Willebrand Factor A1 Domain on Platelet Thrombosis FormationAmerican Society of Hematology

the American Society of Hematology, the 60th Annual Meeting and Exposition (December 1-4, 2018) in San Diego ,
CA Session Name: 332. Anti-thrombotic Therapy: Poster II
Date: Sunday, December 2, 2018 at 6PM PDT

Authors: Kazuya Sakai1, Hideo Yagi1, Masaki Hayakawa1, Tatsuhiko
Someya2, Kaori Harada2, and Masanori Matsumoto1 1. Department of
Blood Transfusion Medicine, Nara Medical University, Nara, Japan 2.
TAGCyx Biotechnologies Inc, Tokyo, Japan

The conference information will be found here.

Sept 28th 2018 Dr. Kazuya Sakai will present data of our anti-coagulant aptamer at the 80th Annual Meeting of the Japanese Society of Hematology on Oct 13th 2018

the 80th Annual Meeting of the Japanese Society of Hematology
Date: October 13th at 9am
Oral presentation OS2-13A-1
Title: “Inhibitory effect of novel DNA aptamer for von Willebrand factor on platelet thrombosis formation”

Kazuya Sakai1, Hideo Yagi1, Masaki Hayakawa1, Kaori Harada2, Tatsuhiko Someya 2, Yoshihiro Fujimura3, Masanori Matsumoto1
1, Department of Blood Transfusion Medicine, Nara Medical University
2, TAGCyx Biotechnologies Inc.
3, Japanese Red Cross Kinki Block Blood Center

Please find the conference details here

Sept 14th 2018 TAGCyx has executed collaborative research agreement with HEALIOS K.K.

TAGCyx has signed collaborative research agreement with HEALIOS K.K. (CEO: Hardy TS Kagimoto, MD, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4593), to generate TAGCyx’ innovative DNA aptamers, Xenoligo®.
Based on the terms of the agreement, TAGCyx will generate Xenoligo®, using its proprietary artificial nucleic acid base pair technology in order to contribute the development of HEALIOS’ regenerative medicine and cell therapeutics.
In return, TAGCyx will receive collaborative research fees as well as milestone payments upon successful generation of the aptamers.
Under the confidentiality of the agreement, further details of the research is not disclosed.